Brian L VanderBeek1, Sarah G Bonaffini2, Liyuan Ma3. 1. Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Leonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: Brian.VanderBeek@uphs.upenn.edu. 2. Lake Erie College of Osteopathic Medicine, Bradenton, Florida. 3. Leonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To determine whether there is a difference in the risk of endophthalmitis after an intravitreal steroid injection compared with an anti-vascular endothelial growth factor (VEGF) agent injection. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 75,249 beneficiaries in a large national US medical claims database representing 406 380 intravitreal injections. METHODS: Data were searched for all intravitreal injections (Current Procedural Terminology 67028) performed between 2003 and 2012. Cohorts were created on the basis of injections using anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone). Endophthalmitis was defined as having a new endophthalmitis diagnosis (International Classification of Diseases 9th Revision 360.0x) and a "tap-and-inject" procedure (Current Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic injection on the same day, between 1 and 14 days post-injection. Exclusion occurred for any history of endophthalmitis, <6 months in the plan, or <1 month follow-up. The main outcome measure was the odds of endophthalmitis using logistic regression while controlling for injection-associated diagnosis, age, race, and gender. RESULTS: A total of 387,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 73 (rate=0.019% or 1/5283 anti-VEGF injections) and 24 (rate=0.13% or 1/778 steroid injections) cases of endophthalmitis, respectively. After controlling for diagnosis, age, race, and gender, the odds ratio (OR) for endophthalmitis occurring was 6.92 (95% confidence interval, 3.54-13.52, P<0.001) times higher post-steroid injection compared with anti-VEGF injections. CONCLUSIONS: The rate of endophthalmitis post-intravitreal steroid injection in a national cohort was 0.13% (1/778 injections). This rate conferred a significantly increased OR of 6.92 for endophthalmitis compared with anti-VEGF agents.
PURPOSE: To determine whether there is a difference in the risk of endophthalmitis after an intravitreal steroid injection compared with an anti-vascular endothelial growth factor (VEGF) agent injection. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 75,249 beneficiaries in a large national US medical claims database representing 406 380 intravitreal injections. METHODS: Data were searched for all intravitreal injections (Current Procedural Terminology 67028) performed between 2003 and 2012. Cohorts were created on the basis of injections using anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone). Endophthalmitis was defined as having a new endophthalmitis diagnosis (International Classification of Diseases 9th Revision 360.0x) and a "tap-and-inject" procedure (Current Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic injection on the same day, between 1 and 14 days post-injection. Exclusion occurred for any history of endophthalmitis, <6 months in the plan, or <1 month follow-up. The main outcome measure was the odds of endophthalmitis using logistic regression while controlling for injection-associated diagnosis, age, race, and gender. RESULTS: A total of 387,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 73 (rate=0.019% or 1/5283 anti-VEGF injections) and 24 (rate=0.13% or 1/778 steroid injections) cases of endophthalmitis, respectively. After controlling for diagnosis, age, race, and gender, the odds ratio (OR) for endophthalmitis occurring was 6.92 (95% confidence interval, 3.54-13.52, P<0.001) times higher post-steroid injection compared with anti-VEGF injections. CONCLUSIONS: The rate of endophthalmitis post-intravitreal steroid injection in a national cohort was 0.13% (1/778 injections). This rate conferred a significantly increased OR of 6.92 for endophthalmitis compared with anti-VEGF agents.
Authors: Mark C Gillies; Lyndell L Lim; Anna Campain; Godfrey J Quin; Wedad Salem; Ji Li; Stephanie Goodwin; Christine Aroney; Ian L McAllister; Samantha Fraser-Bell Journal: Ophthalmology Date: 2014-08-22 Impact factor: 12.079
Authors: Eleonora M Lad; Bradley G Hammill; Laura G Qualls; Fang Wang; Scott W Cousins; Lesley H Curtis Journal: Am J Ophthalmol Date: 2014-05-21 Impact factor: 5.258
Authors: Aaron Y Lee; Lakshmi Akileswaran; Michael D Tibbetts; Sunir J Garg; Russell N Van Gelder Journal: Ophthalmology Date: 2014-11-24 Impact factor: 12.079
Authors: Jasmine H Francis; Brian P Marr; Scott E Brodie; Yves Pierre Gobin; David H Abramson Journal: JAMA Ophthalmol Date: 2014-08 Impact factor: 7.389
Authors: Crystal S Y Cheung; Amanda W T Wong; Alex Lui; Peter J Kertes; Robert G Devenyi; Wai-Ching Lam Journal: Ophthalmology Date: 2012-04-04 Impact factor: 12.079
Authors: Darius M Moshfeghi; Peter K Kaiser; Ingrid U Scott; Jonathan E Sears; Matthew Benz; Juan P Sinesterra; Richard S Kaiser; Sophie J Bakri; Raj K Maturi; Jonathan Belmont; Paul M Beer; Timothy G Murray; Hugo Quiroz-Mercado; William F Mieler Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Mark L Nelson; Matthew T S Tennant; Arunan Sivalingam; Carl D Regillo; Jonathan B Belmont; Adam Martidis Journal: Retina Date: 2003-10 Impact factor: 4.256
Authors: Szilárd Kiss; Ying Liu; Joseph Brown; Nancy M Holekamp; Arghavan Almony; Joanna Campbell; Jonathan W Kowalski Journal: Clin Ophthalmol Date: 2014-08-26
Authors: Yoshihiro Yonekawa; Wei-Chi Wu; Shunji Kusaka; Joshua Robinson; Daishi Tsujioka; Kai B Kang; Michael J Shapiro; Tapas R Padhi; Lubhani Jain; Jonathan E Sears; Ajay E Kuriyan; Audina M Berrocal; Polly A Quiram; Amanda E Gerber; R V Paul Chan; Karyn E Jonas; Sui Chien Wong; C K Patel; Ashkan M Abbey; Rand Spencer; Michael P Blair; Emmanuel Y Chang; Thanos D Papakostas; Demetrios G Vavvas; Robert A Sisk; Philip J Ferrone; Robert H Henderson; Karl R Olsen; M Elizabeth Hartnett; Felix Y Chau; Shizuo Mukai; Timothy G Murray; Benjamin J Thomas; P Anthony Meza; Kimberly A Drenser; Michael T Trese; Antonio Capone Journal: Ophthalmology Date: 2016-05-22 Impact factor: 12.079
Authors: Gary Gensler; Traci E Clemons; Amitha Domalpally; Ronald P Danis; Barbara Blodi; Jack Wells; Michael Rauser; John Hoskins; G Baker Hubbard; Michael J Elman; Gary E Fish; Alexander Brucker; Alan Margherio; Emily Y Chew Journal: Ophthalmol Retina Date: 2018-05